PERTH, Australia – New Australian and European guidelines on managing sexually transmitted diseases (STDs) are driving demand for Speedx Ltd.'s molecular diagnostic that simultaneously detects the Mycoplasma genitalium bacteria and the genetic markers linked to antimicrobial resistance.